mTOR activation in medullary thyroid carcinoma with RAS mutation

European Journal of Endocrinology

Volumn 171, Issue 5, 2014, Pages 633-640

  Lyra, Joana ^a,b   Vinagre, João ^b   Batista, Rui ^b   Pinto, Vasco ^a,b   Prazeres, Hugo ^b,c   Rodrigues, Fernando ^c   Eloy, Catarina ^b   Sobrinho Simões, Manuel ^a,b,d   Soares, Paula ^a,b  

^a University of Porto   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c Instituto Portugues de Oncologia Francisco Gentil Centro Regional de Oncologia de Coimbra SA   (Portugal)

^d HOSPITAL DE SÃO JOÃO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; S6 KINASE; TENSIN; TUMOR MARKER; MTOR PROTEIN, HUMAN; PROTEIN RET; RET PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ADULT; ARTICLE; CHROMOSOME DELETION; CHROMOSOME DELETION 10; CONTROLLED STUDY; DISEASE MARKER; FAMILIAL MEDULLARY THYROID CARCINOMA; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE RET; PREDICTIVE VALUE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SPORADIC MEDULLARY THYROID CARCINOMA; THYROID MEDULLARY CARCINOMA; TUMOR INVASION; WILD TYPE; AGED; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; ONCOGENE RAS; THYROID TUMOR; TRANSCRIPTION INITIATION;

ADULT; AGED; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; HUMANS; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS C-RET; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; TOR SERINE-THREONINE KINASES; TRANSCRIPTIONAL ACTIVATION;

EID: 84910124277     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-14-0389     Document Type: Article

References (24)

1. Jarzab B & Feldt-Rasmussen U. Introduction to European comments on "medullary thyroid cancer: management guidelines of the American Thyroid Association". Thyroid Research 2013 6 (Suppl 1) S1. (doi:10.1186/1756-6614-6-S1-S9)
2. Schlumberger M, Carlomagno F, Baudin E, Bidart JM& SantoroM. New therapeutic approaches to treat medullary thyroid carcinoma. Nature Clinical Practice Endocrinology & Metabolism 2008 4 22-32. (doi:10.1038/ncpendmet0717)
3. Grozinsky-Glasberg S, Rubinfeld H, Nordenberg Y, Gorshtein A, Praiss M, Kendler E, Feinmesser R, Grossman AB & Shimon I. The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells. Molecular and Cellular Endocrinology 2010 315 87-94. (doi:10.1016/j.mce.2009.09.027)
4. Prazeres H, Torres J, Rodrigues F, Couto JP, Vinagre J, Sobrinho-Simoes M & Soares P. How to treat a signal? Current basis for RET-genotype-oriented choice of kinase inhibitors for the treatment of medullary thyroid cancer. Journal of Thyroid Research 2011 2011 678357. (doi:10.4061/2011/678357)
5. Couto JP, Almeida A, Daly L, Sobrinho-Simoes M, Bromberg JF & Soares P. AZD1480 blocks growth and tumourigenesis of RET-activated thyroid cancer cell lines. PLoS ONE 2012 7 e46869. (doi:10.1371/journal.pone.0046869)
6. Almeida MQ & Hoff AO. Recent advances in the molecular pathogenesis and targeted therapies of medullary thyroid carcinoma. Current Opinion in Oncology 2012 24 229-234. (doi:10.1097/CCO.0b013e328351c71a)
7. Prazeres HJ, Rodrigues F, Figueiredo P, Naidenov P, Soares P, Bugalho MJ, Lacerda M, Campos B & Martins TC. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal. Clinical Endocrinology 2006 64 659-666. (doi:10.1111/j.1365-2265.2006.02524.x)
8. Taccaliti A, Silvetti F, Palmonella G & Boscaro M. Genetic alterations in medullary thyroid cancer: diagnostic and prognostic markers. Current Genomics 2013 12 1-8. (doi:10.2174/138920211798120835)
9. Elisei R, Cosci B, Romei C, Bottici V, Renzini G, Molinaro E, Agate L, Vivaldi A, Faviana P, Basolo F et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. Journal of Clinical Endocrinology & Metabolism 2008 93 682-687. (doi:10.1210/jc.2007-1714)
10. Boichard A, Croux L, Al Ghuzlan A, Broutin S, Dupuy C, Leboulleux S, Schlumberger M, Bidart JM & Lacroix L. Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon. Journal of Clinical Endocrinology & Metabolism 2012 97 E2031-E2035. (doi:10.1210/jc.2012-2092)
11. Ciampi R, Mian C, Fugazzola L, Cosci B, Romei C, Barollo S, Cirello V, Bottici V, Marconcini G, Rosa PM et al. Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series. Thyroid 2013 23 1-26. (doi:10.1089/thy.2012.0207)
12. Moura MM, Cavaco BM, Pinto AE & Leite V. High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas. Journal of Clinical Endocrinology & Metabolism 2011 96 E863-E868. (doi:10.1210/jc.2010-1921)
13. Tamburrino A, Molinolo AA, Salerno P, Chernock RD, Raffeld M, Xi L, Gutkind JS, Moley JF,Wells SA Jr & Santoro M. Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastases. Clinical Cancer Research 2012 18 3532-3540. (doi:10.1158/1078-0432.CCR-11-2700)
14. Agrawal N, Jiao YC, Sausen M, Leary R, Bettegowda C, Roberts NJ, Bhan S, Ho AS, Khan Z, Bishop J et al. Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. Journal of Clinical Endocrinology and Metabolism 2013 98 E364-E369. (doi:10.1210/jc.2012-2703)
15. Rapa I, Saggiorato E, Giachino D, Palestini N, Orlandi F, Papotti M & Volante M. Mammalian target of rapamycin pathway activation is associated to RET mutation status in medullary thyroid carcinoma. Journal of Clinical Endocrinology & Metabolism 2011 96 2146-2153. (doi:10.1210/jc.2010-2655)
16. Pitt SC & Chen H. The phosphatidylinositol 3-kinase/akt signaling pathway in medullary thyroid cancer. Surgery 2008 144 721-724. (doi:10.1016/j.surg.2008.06.028)
17. Kouvaraki MA, Liakou C, Paraschi A, Dimas K, Patsouris E, Tseleni-Balafouta S, Rassidakis GZ & Moraitis D. Activation of mTOR signaling in medullary and aggressive papillary thyroid carcinomas. Surgery 2011 150 1258-1265. (doi:10.1016/j.surg.2011.09.022)
18. Cerrato A, De Falco V & Santoro M. Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets. Journal of Molecular Endocrinology 2009 43 143-155. (doi:10.1677/JME-09-0024)
19. Hay N & Sonenberg N. Upstream and downstream of mTOR. Genes and Development 2004 18 1926-1945. (doi:10.1101/gad.1212704)
20. Salmena L, Carracedo A & Pandolfi PP. Tenets of PTEN tumour suppression. Cell 2008 133 403-414. (doi:10.1016/j.cell.2008.04.013)
21. Faggiano A, Ramundo V, Dicitore A, Castiglioni S, Borghi MO, Severino R, Ferolla P, Crino L, Abbruzzese A, Sperlongano P et al. Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study. Journal of Cellular and Molecular Medicine 2012 16 1563-1572. (doi:10.1111/j.1582-4934.2011.01438.x)
22. Aziz SA, Davies M, Pick E, Zito C, Jilaveanu L, Camp RL, Rimm DL, Kluger Y & Kluger HM. Phosphatidylinositol-3-kinase as a therapeutic target in melanoma. Clinical Cancer Research 2009 15 3029-3036. (doi:10.1158/1078-0432.CCR-08-2768)
23. Populo H, Soares P, Rocha AS, Silva P & Lopes JM. Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma. Melanoma Research 2010 20 107-117. (doi:10.1097/CMR.0b013e32832ccd09)
24. Yoon DH, Ryu MH, Park YS, Lee HJ, Lee C, Ryoo BY, Lee JL, Chang HM, Kim TW & Kang YK. Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum. British Journal of Cancer 2012 106 1039-1044. (doi:10.1038/bjc.2012.47)